HER2+ status is associated with aggressive disease and poor patient outcomes1
HER2 positivity is correlated with decreased survival1
These patients did not receive HER2-directed therapy.
P value represents log-rank difference in cumulative survival. HER2 was localized using the ICR12 antibody. Survival curve for patients with HER2+ (IHC 3+; n=50) vs HER2-negative (IHC 0 or 1+; n=85) disease.
Patients with breast tumors that over-express HER2 have shorter time to relapse and reduced overall survival2-6
HER2 positivity is a negative prognostic factor that should be considered even in patients conventionally considered low risk for disease recurrence1,7
- Patients with HER2+ disease with small tumors8
- Patients with HER2+ and HR+ disease9
- Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JMS. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297.
- Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
- Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;6-1(suppl 2):1-13.
- Browne BC, O’Brien NO, Duffy MJ, Crown J, O’Donovan N. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets. 2009;9(3):419-438.
- Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22:6570-6578.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
- Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:121-136.
- Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700-5706.
- Gago FE, Fanelli MA, Ciocca DR. Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol. 2006;98:36-40.